Joshua Ofman Sells 61,665 Shares of GRAIL (NASDAQ:GRAL) Stock

GRAIL, Inc. (NASDAQ:GRAL) President Joshua Ofman sold 61,665 shares of the firm’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $3,078,316.80. Following the completion of the transaction, the president directly owned 371,216 shares of the company’s stock, valued at $18,531,102.72. This represents a 14.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

GRAIL Trading Down 4.1%

NASDAQ:GRAL opened at $45.63 on Friday. GRAIL, Inc. has a 1-year low of $22.30 and a 1-year high of $118.84. The firm has a fifty day simple moving average of $63.91 and a 200 day simple moving average of $79.53. The stock has a market capitalization of $1.87 billion, a PE ratio of -4.08 and a beta of 4.62.

GRAIL (NASDAQ:GRAL) last released its earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, beating the consensus estimate of ($3.33) by $0.89. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%. The business had revenue of $43.60 million during the quarter, compared to analysts’ expectations of $43.33 million. On average, equities analysts predict that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GRAIL

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. N.E.W. Advisory Services LLC bought a new position in GRAIL during the fourth quarter worth $26,000. Caitong International Asset Management Co. Ltd bought a new position in GRAIL during the fourth quarter worth $28,000. Elyxium Wealth LLC bought a new position in GRAIL during the fourth quarter worth $31,000. Comerica Bank lifted its holdings in shares of GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after buying an additional 173 shares in the last quarter. Finally, Intesa Sanpaolo S.p.A. acquired a new stake in shares of GRAIL during the fourth quarter worth $44,000.

GRAIL News Roundup

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Analyst consensus remains constructive: Street coverage still shows an average rating of “Moderate Buy” with a consensus price target around $72.83, implying meaningful upside from current levels. Article Title
• Neutral Sentiment: Mizuho initiated coverage with a “neutral” rating and a $58 price target (roughly mid‑teens to low‑20s % upside vs. current quoted levels); the call is cautious and reflects uncertainty rather than outright bullishness. Article Title
• Neutral Sentiment: Piper Sandler also initiated coverage with a “neutral” rating and a $54 price target, signaling analyst caution and limited near‑term conviction. Article Title
• Negative Sentiment: Reported study setback: coverage initiation notes reference a recent study disappointment that prompted the neutral stances — clinical execution and near‑term data risk are now front and center for investors. Article Title
• Negative Sentiment: Insider selling by senior management: CEO, President and CFO sold sizable blocks on April 8 (CEO ~123,502 shares; President ~61,665; CFO ~45,806), materially reducing their holdings — a strong negative signal to the market and a likely contributor to downward pressure. Article Title

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on GRAL shares. Canaccord Genuity Group decreased their target price on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, February 20th. TD Cowen raised shares of GRAIL from a “hold” rating to a “buy” rating and set a $65.00 price objective for the company in a research report on Wednesday, March 18th. Piper Sandler started coverage on shares of GRAIL in a research report on Friday. They set a “neutral” rating and a $54.00 price objective for the company. Morgan Stanley reduced their price objective on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Finally, Robert W. Baird set a $82.00 price objective on shares of GRAIL in a research report on Friday, February 20th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $68.63.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.